Healthcare provider profile · identity verified

Kyle Mitcham Masters, MD

Internal Medicine · APO, AE · NPI 1194040840

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	625	182
Lisinopril	Lisinopril	359	108
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	283	91
Levothyroxine Sodium	Levothyroxine Sodium	269	70
Oxycodone Hcl	Oxycodone Hcl	269	60
Losartan Potassium	Losartan Potassium	262	83
Amlodipine Besylate	Amlodipine Besylate	253	77
Tamsulosin Hcl	Tamsulosin Hcl	211	54
Trazodone Hcl	Trazodone Hcl	208	69
Gabapentin	Gabapentin	192	65
Simvastatin	Simvastatin	187	55
Pantoprazole Sodium	Pantoprazole Sodium	183	60
Albuterol Sulfate Hfa	Albuterol Sulfate	166	64
Rosuvastatin Calcium	Rosuvastatin Calcium	156	45
Metoprolol Succinate	Metoprolol Succinate	153	45
Metoprolol Tartrate	Metoprolol Tartrate	145	45
Metformin Hcl Er	Metformin Hcl	136	43
Metformin Hcl	Metformin Hcl	130	46
Duloxetine Hcl	Duloxetine Hcl	116	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	107	35
Warfarin Sodium	Warfarin Sodium	107	34
Spironolactone	Spironolactone	103	31
Glipizide	Glipizide	102	32
Pravastatin Sodium	Pravastatin Sodium	100	29
Meloxicam	Meloxicam	95	41
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	93	28
Pradaxa	Dabigatran Etexilate Mesylate	90	28
Atenolol	Atenolol	86	30
Jardiance	Empagliflozin	86	27
Potassium Chloride	Potassium Chloride	83	31
Furosemide	Furosemide	78	33
Omeprazole	Omeprazole	77	23
Alendronate Sodium	Alendronate Sodium	76	23
Allopurinol	Allopurinol	74	18
Escitalopram Oxalate	Escitalopram Oxalate	71	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	70	21
Hydrochlorothiazide	Hydrochlorothiazide	64	20
Humulin N	Insulin Nph Human Isophane	60	22
Ozempic	Semaglutide	60	suppressed
Donepezil Hcl	Donepezil Hcl	58	13
Lorazepam	Lorazepam	58	19
Pregabalin	Pregabalin	57	19
Sertraline Hcl	Sertraline Hcl	55	20
Alvesco	Ciclesonide	53	19
Methocarbamol	Methocarbamol	53	suppressed
Fluticasone Propionate	Fluticasone Propionate	52	16
Quetiapine Fumarate	Quetiapine Fumarate	51	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	50	14
Mirtazapine	Mirtazapine	49	suppressed
Ondansetron Odt	Ondansetron	49	16
Finasteride	Finasteride	46	13
Xarelto	Rivaroxaban	45	12
Carvedilol	Carvedilol	43	14
Torsemide	Torsemide	43	15
Clopidogrel	Clopidogrel Bisulfate	42	15
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	42	11
Morphine Sulfate Er	Morphine Sulfate	41	15
Citalopram Hbr	Citalopram Hydrobromide	40	13
Wixela Inhub	Fluticasone Propion/Salmeterol	40	14
Prednisone	Prednisone	39	21
Eliquis	Apixaban	38	11
Tramadol Hcl	Tramadol Hcl	37	14
Montelukast Sodium	Montelukast Sodium	36	suppressed
Propranolol Hcl	Propranolol Hcl	36	14
Bupropion Xl	Bupropion Hcl	34	suppressed
Baclofen	Baclofen	32	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	31	15
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	31	11
Alprazolam	Alprazolam	30	suppressed
Hydrocortisone	Hydrocortisone	30	24
Acyclovir	Acyclovir	29	11
Famotidine	Famotidine	29	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	29	21
Fluoxetine Hcl	Fluoxetine Hcl	28	suppressed
Lovastatin	Lovastatin	28	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	27	suppressed
Spiriva Respimat	Tiotropium Bromide	27	suppressed
Valacyclovir	Valacyclovir Hcl	27	suppressed
Nystatin	Nystatin	26	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	26	12
Testosterone Cypionate	Testosterone Cypionate	25	suppressed
Tizanidine Hcl	Tizanidine Hcl	25	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	suppressed
Azelastine Hcl	Azelastine Hcl	24	12
Humulin R	Insulin Regular, Human	24	suppressed
Breyna	Budesonide/Formoterol Fumarate	23	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	22	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	22	suppressed
Terazosin Hcl	Terazosin Hcl	22	suppressed
Estradiol	Estradiol	21	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Nifedipine Er	Nifedipine	21	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	21	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	18	suppressed
Digoxin	Digoxin	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Clonazepam	Clonazepam	16	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	16	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	16	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	15	suppressed
Colestipol Hcl	Colestipol Hcl	14	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	14	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Tacrolimus	Tacrolimus	14	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Primidone	Primidone	13	suppressed
Humalog	Insulin Lispro	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Lidocaine Hcl Viscous	Lidocaine Hcl	11	suppressed
Metronidazole	Metronidazole	11	suppressed
Naloxone Hcl	Naloxone Hcl	11	suppressed
Tadalafil	Tadalafil	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error